ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,730
-370 (-3.06%)
Oct 30, 2025, 3:30 PM KST
-3.06%
Market Cap127.88B
Revenue (ttm)5.83B
Net Income (ttm)-18.24B
Shares Out10.90M
EPS (ttm)-1,763.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume71,210
Average Volume112,207
Open12,140
Previous Close12,100
Day's Range11,410 - 12,140
52-Week Range10,000 - 22,800
Betan/a
RSI48.96
Earnings Daten/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2024, ENCell's revenue was 7.21 billion, a decrease of -31.51% compared to the previous year's 10.53 billion. Losses were -15.21 billion, 201.0% more than in 2023.

Financial Statements

News

There is no news available yet.